Navigation Links
Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Date:8/16/2012

THE WOODLANDS, Texas, Aug. 16, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

The Phase 1 study of LX2931, an inhibitor of sphingosine-1-phosphate lyase, was a dose-ranging study to explore higher doses of LX2931 in patients with rheumatoid arthritis. The study involved 10 patients with rheumatoid arthritis, eight of whom were randomized to LX2931 and two to placebo.  The primary endpoint in the study was an evaluation of the safety and tolerability of escalating doses of LX2931 compared with placebo over 12 weeks in subjects with active rheumatoid arthritis.  Secondary endpoints included pharmacokinetic and disease activity measures. 

Patients in the study received increasing doses over the course of the study, beginning at 50 mg QD and escalating to 500 mg QD.  LX2931 was well-tolerated at all doses evaluated, with no serious adverse events and no withdrawals due to adverse events. Seven of eight patients on LX2931 achieved drug trough levels greater than 60 ng/ml, a pharmacokinetic measure which a post-hoc analysis of data from a prior Phase 2 study of LX2931 had suggested was associated with better responses in American College of Rheumatology (ACR) measures in the study.  Six of the eight LX2931-treated patients experienced a drop from baseline in the DAS28 score of greater than or equal to 1.2, as did both placebo patients.  ACR20 and ACR50 responses were achieved at varying frequencies in both LX2931-treated and placebo patients, but two of eight patients dosed with LX2931 achieved an ACR70 response during the course of the study,
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
3. Lexicon to Provide Second Quarter 2012 Financial Results
4. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
5. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
6. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
7. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
8. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
10. Lexicon to Provide First Quarter 2012 Financial Results
11. Nouveau Life Pharmaceuticals (NOUV) Releases Calcium & Vitamin D for Strong Bones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014  As the building ... a company access to diverse skill sets and ... round-the clock business hours for efficiency. However, effectively ... According to recent research, more ... as seeing a project not move forward due ...
(Date:10/22/2014)... Investor-Edge has initiated coverage on the following ... Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), Threshold ... Inc. (NASDAQ: IDRA ), and Merrimack Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,419.48, up 2.40%, the Dow Jones Industrial Average ...
(Date:10/22/2014)... 22, 2014  Paper Pak Industries, a manufacturer ... ® Body Guard Bio, a disposable, highly ... bacteria and virus while protecting service providers and ... features a rugged, external nylon shell, watertight zipper, ... leak-proof inner chamber that contains contaminated and potentially ...
Breaking Medicine Technology:Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2
... , MORRISTOWN, N.J., Dec. 14 Watson ... new program encouraging health professionals to help maintain the bone ... deprivation therapy (ADT). Nearly two million men are receiving ... effective and considered the "gold therapy," can cause bone loss ...
... , DOVER, Del., Dec. 14 Ohr Pharmaceutical ... selected Allen & Caron Inc, headquartered in Irvine, CA, ... its agency for investor relations and corporate communications. ... on developing advanced drugs for underserved therapeutic needs. The ...
Cached Medicine Technology:Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 2Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 3Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 4Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy 5Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 2Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 3
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... herpes simplex -- might increase the risk of Alzheimer,s disease, ... a carrier of certain antibodies to the virus can double ... "The identification of a treatable cause [herpes simplex] of the ... Dr. Hugo Lovheim, an associate professor in the department of ...
(Date:10/25/2014)... News) -- Current osteoporosis screening guidelines and tools ... risk for osteoporosis-related fractures, a new study says. ... need tools that help us accurately predict who ... can target these at-risk people for preventive measures," ... in the division of general internal medicine and ...
(Date:10/22/2014)... On Saturday, October 25, 2014, the Brownsville ... health and fitness fair ¡Vive tu vida! Get Up! Get ... nutrition for better health and wellness for people of all ... open to the public, will be held at Dean Porter ... to 1:00 pm. , “¡Vive tu Vida! Get Up! ...
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... 22, 2014 The Louis ... is dedicated to distribute health information technology innovation ... worldwide announced the development of six key guiding ... when receiving healthcare. These are an expansion of ... “providing care that is respectful of and responsive ...
Breaking Medicine News(10 mins):Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2
... COLUMBIA, Mo. A University of Missouri researcher has ... in protein, increases satiety and reduces hunger throughout the ... the researchers found that eating a protein-rich breakfast reduces ... behavior. "Everyone knows that eating breakfast is important, ...
... N.J. (May 19, 2011) The John Theurer Cancer Center ... with The Promise Foundation to host a skin cancer screening ... program will feature educational information on skin cancer prevention and ... community. "Skin cancer can be a devastating ...
... release is available in French and German ... in the animal kingdom. However, how jaws developed in the ... of paleontologist Nicolas Goudemand, a team of researchers from the ... about solving this puzzle. Living and extinct jawless animals can ...
... Dozens of studies on whether moderate exercise can curb ... to an apparent contradiction: it seems to work in ... in treatment trials. A new study may explain why ... explanation suggested in the results of research led by ...
... 16 countries announced new commitments to dramatically reduce maternal, ... Strategy for Women,s and Children,s Health. "Political ... health is reaching new and encouraging heights. The commitments ... that saving the lives of the most vulnerable can ...
... The American Society of Clinical Oncology (ASCO) today highlighted ... than 4,000 abstracts publicly posted online at www.asco.org in ... 17 plenary, late-breaking and other major studies will be ... The meeting, which is expected to ...
Cached Medicine News:Health News:Eat a protein-rich breakfast to reduce food cravings, prevent overeating later, researcher finds 2Health News:The peculiar feeding mechanism of the first vertebrates 2Health News:Exercise helps women fight smoking cravings, but effect is short-lived 2Health News:New commitments to save women and children 2Health News:New commitments to save women and children 3Health News:New commitments to save women and children 4Health News:New commitments to save women and children 5Health News:New commitments to save women and children 6Health News:New commitments to save women and children 7Health News:New commitments to save women and children 8Health News:ASCO releases studies from upcoming annual meeting 2Health News:ASCO releases studies from upcoming annual meeting 3
... tip, the Finntip Wide is designed especially ... like genomic DNA. This tip eliminates the ... is excellent for use with extremely viscous ... diameter of the orifice is 1.1 mm ...
For restriction digests, immuno-precipitations, enzyme assays, TLC spotting and others...
The Ultra Micro tip for the Eppendorf and Nichiryo/BenchMate 0.5-10 L pipettors is perfect for working with low volume samples....
... easy way to order tips. Each box contains ... D10mL, which contains 200 tips (4 bags of ... Packs of 200 tips per pack. Bulk Packs ... easily be opened for quick access to Gilsons ...
Medicine Products: